entertainment -WSS

entertainment

author：leisure time 2025-09-06 03:54:53 - browse：2184

Closeup of a human brain affected by Alzheimer's disease, on display at the Museum of Neuroanatomy at the University at Buffalo in Buffalo, N.Y. — A brain affected by Alzheimer's disease, at the Museum of Neuroanatomy at the University at Buffalo. David Duprey/AP

Investigators on Wednesday released the first detailed case report about a patient who died after receiving lecanemab, providing a new glimpse into safety concerns surrounding the closely watched experimental Alzheimer’s drug.

An unpublished version of the report was previously written about by Science in November, one of three deaths from the lecanemab trials revealed by Science and STAT. But the published version, in the New England Journal of Medicine, will allow doctors to evaluate the case as they consider whether and how to use a treatment that could be approved by the FDA as soon as this week.

This “will have greater impact on clinicians because it is peer-reviewed and published in the New England Journal,” said Lon Schneider, an Alzheimer’s expert at University of Southern California, who was not affiliated with the work.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How to save PrEP access — and even expand it
Next article： 2023 STAT Wunderkinds: get to know the winners

entertainment

WSS

IVG is promising — but it won’t replace IVF quite yet

What will Novo Nordisk's VC do with its influx of cash?

Senate committee scrutinizes Medicare Advantage brokers

Stop Congress from blocking public access to science

2023 STAT Wunderkinds: get to know the winners

Beam Therapeutics to lay off 20% of its staff, re

knowledge

entertainment

entertainment

Virginia high school admissions case could be legal follow

New oral drug delivery patch is modeled after octopus tentacles

Sports medicine is finally prioritizing gender equality

Studies point to risks of excluding people with obesity from drug trials

Cancer drug shortages should be causing more outrage

CRISPR base editing slashes cholesterol levels in monkeys

Medicare proposal to cover medical devices draws a mixed reaction

Will Ozempic

What does generative AI mean for health care? We asked experts

Will Ozempic

focus

Some top drug companies are starting to take action on climate

FDA struggles to regulate food additives, sometimes for decades

UnitedHealth’s board chair also owns a personal investment firm

Solve the antibiotic resistance crisis with preventive drugs

Impact of Dobbs ruling felt at reproductive medicine meeting

FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

leisure time

focus

entertainment

entertainment